Related Experiment Video

Updated: Aug 29, 2026

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

Detection of mutations in the mitogen-activated protein kinase pathway in human melanoma

Janivette Alsina1, David H Gorsk, F Joseph Germino

  • 1Division of Surgical Oncology, The University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, The Cancer Institute of New Jersey, New Brunswick, New Jersey 08901, USA.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|December 26, 2003
PubMed
Abstract

Insights

Activating mutations in B-RAF and N-RAS genes are common in melanoma, affecting the mitogen-activated protein kinase (MAPK) pathway. This study developed a sensitive method to detect these mutations, crucial for understanding melanoma development.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Activating point mutations in B-RAF are frequently observed in melanoma.
  • The mitogen-activated protein kinase (MAPK) pathway plays a critical role in cellular signaling and is often dysregulated in cancer.
  • Detecting specific gene mutations in heterogeneous tumor samples presents a technical challenge.

Purpose of the Study:

  • To develop and validate a novel method for detecting activating point mutations in B-RAF and N-RAS genes within heterogeneous melanoma tissues.
  • To determine the incidence of these mutations in a cohort of human melanoma samples.
  • To investigate the functional consequence of these mutations on MAPK pathway activation.

Main Methods:

  • A site-directed mutagenesis technique was employed to introduce unique restriction sites into cDNA sequences harboring specific B-RAF and N-RAS mutations.
  • Eighty-five melanoma samples (primary and metastatic) were screened for common B-RAF (V599E) and N-RAS (Q61R, Q61K) mutations.
  • Western blotting was utilized to assess the phosphorylation status of extracellular signal-regulated kinase 1/2 (ERK1/2) as a readout of MAPK pathway activation.

Main Results:

  • The V599E B-RAF mutation was detected in 39% of samples (20 of 50), with varying frequencies across primary, regional, nodal, and distant metastases.
  • Activating mutations in N-RAS (Q61R or Q61K) were identified in 17 samples.
  • MAPK pathway activation, indicated by phosphorylated ERK1/2, was significantly higher in samples with B-RAF or N-RAS mutations compared to wild-type samples.
  • The developed detection method demonstrated high sensitivity and specificity, with no false positives.

Conclusions:

  • Approximately 60% of the tested melanoma samples harbored activating mutations in the MAPK pathway (B-RAF or N-RAS).
  • These activating mutations lead to the functional activation of the MAPK pathway.
  • The findings underscore the importance of MAPK pathway mutations in the pathogenesis of melanoma and highlight the utility of the developed detection method.

More Related Videos

A 3D Organotypic Melanoma Spheroid Skin Model08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...